Sign inCreate account

Report workspace tools

NCT02918747UNKNOWNanonymous

P-Gemoxd Regimen Followed by Radiotherapy Versus P-CHOP Regimen Followed by Radiotherapy in ENKTL With Early Stage: a Randomized, Multicenter, Open-label, Phase 2 Study

Sponsor

Source record

Hunan Cancer Hospital

Phase

Source record

PHASE2

Modality

AI-normalized

small molecule

Target

AI-normalized

pegaspargase, Gemcitabine, Oxaliplatin, Dexamethasone, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, IMRT

Indication / condition

AI-normalized

Lymphoma

Intervention

Source record

pegaspargase, Gemcitabine, Oxaliplatin, Dexamethasone, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, IMRT

Source & freshness

Source record

NCT ID

NCT02918747

Original source

ClinicalTrials.gov

Source last updated

Jan 28, 2020

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT02918747

Title

P-Gemoxd Regimen Followed by Radiotherapy Versus P-CHOP Regimen Followed by Radiotherapy in ENKTL With Early Stage: a Randomized, Multicenter, Open-label, Phase 2 Study

Sponsor

Hunan Cancer Hospital

Status

UNKNOWN

Phase

PHASE2

Condition raw

Lymphoma

Condition normalized

Lymphoma

Modality raw

small molecule

Modality normalized

small molecule

Target raw

pegaspargase, Gemcitabine, Oxaliplatin, Dexamethasone, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, IMRT

Target normalized

pegaspargase, Gemcitabine, Oxaliplatin, Dexamethasone, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, IMRT

Interventions

pegaspargase, Gemcitabine, Oxaliplatin, Dexamethasone, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, IMRT

Public preview

Source record

Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive subtype of non-Hodgkin's lymphoma and shows extremely poor survival. Several retrospective studies and singe-arm prospective phase 2 studies have shown that pegaspargase combined Gemox or CHOP regimen achieved a promising efficacy in treatment of ENKTL. However, there is no prospective study to compare the efficacy of these two regimens. This prospective pilot study to compare the efficacy and safety of the P-Gemoxd chemotherapy regimen with those of the P-CHOP regimen for stage IE to IIE ENKTL.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

P-Gemoxd Regimen Followed by Radiotherapy Versus P-CHOP Regimen Followed by Radiotherapy in ENKTL With Early Stage: a Randomized, Multicenter, Open-label, Phase 2 Study

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT02918747

Status

UNKNOWN

Phase

PHASE2

Sponsor

Hunan Cancer Hospital

Executive brief

Investment-Ready Snapshot

Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive subtype of non-Hodgkin's lymphoma and shows extremely poor survival. Several retrospective studies and singe-arm prospective phase 2 studies have shown that pegaspargase combined Gemox or CHOP regimen achieved a promising efficacy in treatment of ENKTL. However, there is no prospective study to compare the efficacy of these two regimens. This prospective pilot study to compare the efficacy and safety of the P-Gemoxd chemotherapy regimen with those of the P-CHOP regimen for stage IE to IIE ENKTL.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJan 28, 2020
Internal syncJun 11, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT02918747

Indication

Lymphoma

Modality

small molecule

Target

pegaspargase, Gemcitabine, Oxaliplatin, Dexamethasone, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, IMRT

Intervention

pegaspargase, Gemcitabine, Oxaliplatin, Dexamethasone, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, IMRT

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.